AAM Issue Brief: Biosimilars Medicare Part B | Association for Accessible Medicines

AAM Issue Brief: Biosimilars Medicare Part B

The Biosimilars Council Opposes Efforts to Prohibit Biosimilars From Receiving Pass-Through Status in the Medicare Part B Program

Despite the importance of biosimilars to reducing the cost of medicine, policymakers recently included a provision in a proposed bill that would have prohibited biosimilars from receiving pass-through status in Medicare Part B. While this provision was ultimately removed from the final legislation, the Biosimilars Council is concerned that it continues to be proffered by certain brand biologic manufacturers as a means to stifle biosimilar competition. The prohibition of biosimilars from receiving pass-through status would reduce patient access to these affordable alternatives to brand biologic medicines, disincentivize manufacturer investment, and significantly weaken the nascent biosimilars market in the United States.

Read Issue Brief

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.